On this page

Sodium Chloride

Prescription NDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Sodium Chloride
Generic name
Sodium Chloride
Dosage form
Irrigant
Route
Irrigation
Marketing category
NDA · NDA
Labeler
Baxter Healthcare Company
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
3
NDC product codes
7
Packages
16
Data completeness
83% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Sodium Chloride .9 g/100mL 707251 View
Sodium Chloride 9 g/1000mL 707251 View
Sodium Chloride 900 mg/100mL 707251 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Irrigant
Route of administration
Irrigation
Presentations
23

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Increased Large Intestinal Motility [PE] PE All 83 members
Inhibition Large Intestine Fluid/Electrolyte Absorption [PE] PE All 83 members
Osmotic Activity [MoA] MoA All 105 members
Osmotic Laxative [EPC] EPC All 103 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
017867
Application type
NDA · New Drug Application
Approval date
May 30, 1980
Sponsor
BAXTER HLTHCARE
Products on application
1
Submissions recorded
43
Products approved under application 017867.
Product Trade name Form Strength Ingredient Status TE Flags
017867-001 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER SOLUTION SODIUM CHLORIDE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 017867.
Type No. Action Status Date Review
Supplement 48 Manufacturing (CMC) Approved August 29, 2001 Standard
Supplement 47 Manufacturing (CMC) Approved January 28, 2000 Standard
Supplement 46 Labeling Approved May 26, 1999 —
Supplement 45 Manufacturing (CMC) Approved April 29, 1997 Standard
Supplement 43 Manufacturing (CMC) Approved September 30, 1994 Standard
Supplement 44 Manufacturing (CMC) Approved February 18, 1994 Standard
Supplement 42 Manufacturing (CMC) Approved December 8, 1993 Standard
Supplement 40 Labeling Approved May 8, 1991 —
Supplement 39 Manufacturing (CMC) Approved March 26, 1991 Standard
Supplement 37 Manufacturing (CMC) Approved February 15, 1991 Standard
Supplement 38 Manufacturing (CMC) Approved May 24, 1990 Standard
Supplement 36 Manufacturing (CMC) Approved July 26, 1989 Standard
Supplement 35 Manufacturing (CMC) Approved January 12, 1989 Standard
Supplement 33 Manufacturing (CMC) Approved July 25, 1987 Standard
Supplement 32 Manufacturing (CMC) Approved May 28, 1987 Standard
Supplement 31 Manufacturing (CMC) Approved February 27, 1986 Standard
Supplement 22 Manufacturing (CMC) Approved August 28, 1985 Standard
Supplement 21 Manufacturing (CMC) Approved August 28, 1985 Standard
Supplement 28 Manufacturing (CMC) Approved June 13, 1985 Standard
Supplement 30 Manufacturing (CMC) Approved April 15, 1985 Standard
Supplement 29 Labeling Approved April 10, 1985 —
Supplement 27 Labeling Approved January 26, 1985 —
Supplement 19 Manufacturing (CMC) Approved January 24, 1985 Standard
Supplement 6 Manufacturing (CMC) Approved January 24, 1985 Standard
Supplement 20 Manufacturing (CMC) Approved March 16, 1984 Standard
Supplement 26 Manufacturing (CMC) Approved February 28, 1984 Standard
Supplement 15 Labeling Approved December 22, 1982 —
Supplement 14 Manufacturing (CMC) Approved December 22, 1982 Standard
Supplement 24 Labeling Approved December 3, 1982 —
Supplement 23 Manufacturing (CMC) Approved December 3, 1982 Standard
Supplement 11 Manufacturing (CMC) Approved June 3, 1982 Standard
Supplement 9 Manufacturing (CMC) Approved April 16, 1982 Standard
Supplement 17 Labeling Approved February 17, 1982 —
Supplement 8 Manufacturing (CMC) Approved December 21, 1981 Standard
Supplement 13 Manufacturing (CMC) Approved November 20, 1981 Standard
Supplement 7 Manufacturing (CMC) Approved November 13, 1981 Standard
Supplement 10 Manufacturing (CMC) Approved November 9, 1981 Standard
Supplement 5 Manufacturing (CMC) Approved June 29, 1981 Standard
Supplement 4 Manufacturing (CMC) Approved May 29, 1981 Standard
Supplement 3 Manufacturing (CMC) Approved January 21, 1981 Standard
Supplement 2 Manufacturing (CMC) Approved August 6, 1980 Standard
Supplement 1 Manufacturing (CMC) Approved July 31, 1980 Standard
Original application 1 Type 5 - New Formulation or New Manufacturer Approved May 30, 1980 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251102). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20251102 HUMAN PRESCRIPTION DRUG · 20251031 HUMAN PRESCRIPTION DRUG · 20250709

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE This sterile, nonpyrogenic electrolyte solution is indicated for all general irrigation, washing, rinsing and dilution purposes including blood cell washing (when used in conjunction with automated intraoperative blood salvaging equipment).

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION The dose is dependent upon the capacity or surface area of the structure to be irrigated and the nature of the procedure. When used as a diluent or vehicle for other drugs, the manufacturer's recommendations should be followed. For use in cell washing, the manufacturer's recommendations for blood salvaging and red cell processing should be followed. Drug Interactions Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution container permits. See PRECAUTIONS .

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS 0.9% Sodium Chloride Irrigation USP is not for injection by usual parenteral routes. An electrolyte solution should not be used for irrigation during electrosurgical procedures.

WARNINGS FOR IRRIGATION ONLY. NOT FOR INJECTION. Irrigating fluids have been demonstrated to enter the systemic circulation in relatively large volumes; thus, irrigation solutions must be regarded as systemic drugs. Absorption of large amounts can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the administered parenteral solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration. Do not warm above 150°F (66°C). After opening container, its contents should be used promptly to minimize the possibility of bacterial growth or pyrogen formation. Discard unused portion of irrigating solution since it contains no preservatives.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Possible adverse effects arising from the irrigation of body cavities, tissues, or indwelling catheters and tubes can be minimized when proper procedures are followed. Displaced catheters or drainage tubes can lead to irrigation or infiltration of unintended structures or cavities. Excessive volume or pressure during irrigation of closed cavities may cause undue distension or disruption of tissues. Accidental contamination from careless technique may transmit infection. If an adverse reaction does occur, discontinue administration of the irrigant, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

Drug Interactions

openFDA Drug Labeling

Drug Interactions Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic technique. Mix thoroughly. Do not store.

Description

openFDA Drug Labeling

DESCRIPTION These products are sterile, nonpyrogenic solutions of electrolytes in water for injection intended only for sterile irrigation, washing, rinsing and dilution purposes. Each 100 mL of 0.9% Sodium Chloride Irrigation, USP contains: Sodium chloride 900 mg; pH 5.6 (4.5 to 7.0). May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. The solution is isotonic (308 mOsmol/liter, CALC.) and has the following electrolyte content (mEq/liter): Na + 154; Cl − 154. These irrigations contain no bacteriostat, antimicrobial agent or added buffer and are intended only for use as single-dose or short procedure irrigation. When smaller volumes are required the unused portion should be discarded. Each of these irrigations may be classified as a sterile irrigant, wash, rinse, diluent and pharmaceutical vehicle. Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water. Water for Injection, USP is chemically designated H 2 O. The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. The semi-rigid container is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The container requires no vapor barrier to maintain the proper drug concentration. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.

OVERDOSAGE In the event of overhydration or solute overload, reevaluate the patient’s condition, and institute appropriate corrective treatment. Intravascular volume overload may respond to hemodialysis. See WARNINGS , PRECAUTIONS , and ADVERSE REACTIONS .

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED 0.9% Sodium Chloride Irrigation, USP: Container Size NDC Single-dose 500 mL semi-rigid irrigation container 0409-6138-03 Manufactured for ICU Medical, Inc., Lake Forest, Illinois, 60045, USA Single-dose 500 mL semi-rigid irrigation container 0990-6138-03 Single-dose 250 mL semi-rigid irrigation container 0409-6138-22 Single-dose 250 mL semi-rigid irrigation container 0990-6138-22 Single-dose 1000 mL semi-rigid irrigation container 0409-7138-09 Single-dose 1000 mL semi-rigid irrigation container 0990-7138-09 Single-dose 1500 mL semi-rigid irrigation container 0409-7138-36 Single-dose 1500 mL semi-rigid irrigation container 0990-7138-36 Single-dose 1000 mL flexible irrigation container 0409-7972-05 Manufactured by ICU Medical, Inc., Lake Forest, Illinois, 60045, USA Single-dose 1000 mL flexible irrigation container 0990-7972-05 Single-dose 2000 mL flexible irrigation container 0409-7972-07 Single-dose 2000 mL flexible irrigation container 0990-7972-07 ICU Medical is transitioning NDC codes from "0409" to "0990" labeler code. Both NDC codes are expected to be in the market for a period of time. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. Revised: July, 2018 EN-4660 ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

Adverse event reports

Source: openFDA FAERS
271,787
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: SODIUM CHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class II April 16, 2025 B. Braun Medical Inc Presence of Particulate Matter Ongoing
Class II March 31, 2021 ICU Medical Inc Presence of particulate matter.one confirmed customer report of particulate matter within two semi-rigid bottles identified prior to use Terminated
Class II November 27, 2019 Baxter Healthcare Corporation Lack of Assurance of Sterility: Product has the potential to leak. Terminated
Class II March 7, 2018 B. Braun Medical Inc Presence of Particulate Matter: Customer complaint of particulate matter which has been identified as polyethylene, which is consistent with the material used to manufacture the container cap was received. Terminated
Class II March 9, 2016 Baxter Healthcare Corp. PRESENCE OF PARTICULATE MATTER: Product complaint for the presence of particulate matter identified as an insect. Terminated
Class II May 7, 2014 Baxter Healthcare Corp. Presence of Particulate Matter: Nylon fibers found in a bottle of 0.9% sodium chloride for irrigation. Terminated

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0264-2201-00 0264-2201 B. Braun Medical Inc. 16 CONTAINER in 1 CASE (0264-2201-00) / 1000 mL in 1 CONTAINER September 14, 2009
0264-2201-10 0264-2201 B. Braun Medical Inc. 16 CONTAINER in 1 CASE (0264-2201-10) / 500 mL in 1 CONTAINER September 14, 2009
0338-0047-44 0338-0047 Baxter Healthcare Company 14 BAG in 1 CARTON (0338-0047-44) / 1000 mL in 1 BAG May 30, 1980
0338-0047-46 0338-0047 Baxter Healthcare Company 6 BAG in 1 CARTON (0338-0047-46) / 2000 mL in 1 BAG May 30, 1980
0338-0047-47 0338-0047 Baxter Healthcare Company 4 BAG in 1 CARTON (0338-0047-47) / 3000 mL in 1 BAG May 30, 1980
0338-0110-04 0338-0110 Baxter Healthcare Company 4 BAG in 1 CARTON (0338-0110-04) / 3000 mL in 1 BAG (0338-0110-01) November 13, 2024
0338-9834-04 0338-9834 Baxter Healthcare Company 4 BAG in 1 CARTON (0338-9834-04) / 3000 mL in 1 BAG (0338-9834-01) December 3, 2024
0338-0047-27 0338-0047 Baxter Healthcare Corporation 4 BAG in 1 CARTON (0338-0047-27) / 3000 mL in 1 BAG May 30, 1980
0338-0047-29 0338-0047 Baxter Healthcare Corporation 2 BAG in 1 CARTON (0338-0047-29) / 5000 mL in 1 BAG May 30, 1980
0338-0048-02 0338-0048 Baxter Healthcare Corporation 24 BOTTLE, PLASTIC in 1 CARTON (0338-0048-02) / 250 mL in 1 BOTTLE, PLASTIC December 31, 1974
0338-0048-03 0338-0048 Baxter Healthcare Corporation 18 BOTTLE, PLASTIC in 1 CARTON (0338-0048-03) / 500 mL in 1 BOTTLE, PLASTIC December 31, 1974
0338-0048-04 0338-0048 Baxter Healthcare Corporation 12 BOTTLE, PLASTIC in 1 CARTON (0338-0048-04) / 1000 mL in 1 BOTTLE, PLASTIC December 31, 1974
0338-0051-44 0338-0051 Baxter Healthcare Corporation 1000 mL in 1 BAG (0338-0051-44) May 17, 1985
0990-7972-05 0990-7972 ICU Medical Inc. 12 BAG in 1 CASE (0990-7972-05) / 1000 mL in 1 BAG January 1, 2020
0990-7972-07 0990-7972 ICU Medical Inc. 6 BAG in 1 CASE (0990-7972-07) / 2000 mL in 1 BAG August 1, 2019
0990-7972-08 0990-7972 ICU Medical Inc. 4 POUCH in 1 CASE (0990-7972-08) / 1 BAG in 1 POUCH / 3000 mL in 1 BAG July 1, 2019
0264-2201 0264-2201 B. Braun Medical Inc. — September 14, 2009
0338-0047 0338-0047 Baxter Healthcare Company — May 30, 1980
0338-0110 0338-0110 Baxter Healthcare Company — November 13, 2024
0338-9834 0338-9834 Baxter Healthcare Company — December 3, 2024
0338-0048 0338-0048 Baxter Healthcare Corporation — December 31, 1974
0338-0051 0338-0051 Baxter Healthcare Corporation — May 17, 1985
0990-7972 0990-7972 ICU Medical Inc. — July 1, 2019

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records

Generated September 25, 2026 · 13 sections on this page.